Analyst downgrades: ABH, GSK, AZN and COF
Posted Apr 18th 2008 11:05AM by Eric Buscemi
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Nokia Corp. (NOK)
.gif)
MOST NOTEWORTHY: AbitibiBowater, GlaxoSmithKline, AstraZeneca and Capital One were today's noteworthy downgrades:
- Lehman downgraded AbitibiBowater (NYSE: ABH) to Equal Weight from Overweight citing dilution from the recent $350M convertible offering, cost pressures, and a more cautious outlook near-term for pulp markets.
- JP Morgan cut GlaxoSmithKline (NYSE: GSK) and AstraZeneca (NYSE: AZN) to Underweight from Neutral on long-term earnings growth concerns.
- Keefe Bruyette lowered Capital One (NYSE: COF) to Underperform from Market Perform to reflect the company's credit outlook.
OTHER DOWNGRADES:
- Nokia (NYSE: NOK) was downgraded to Neutral from Buy at UBS and to Underweight from Overweight at JP Morgan.
- Textron (NYSE: TXT) was cut at Credit Suisse to Neutral from Outperform.
- Merriman downgraded Blue Coat Systems (NASDAQ: BCSI) to Neutral from Buy.
Tags: abh, AbitibiBowater, analyst, astrazeneca, azn, bcsi, blue coat systems, BlueCoatSystems, capital one, CapitalOne, cof, downgrade, glaxosmithkline, gsk, nok, nokia, textron, txt
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
